Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Moderna announced Monday that its COVID-19 vaccine candidate, identified as mRNA-1273, is moving forward to the final phase of testing. The biotech firm expects the crucial stage of the study will enroll up to 30,000 volunteers across the United States.
COVID-19 vaccine: Promising candidate enters final efficacy testing on 30,000 human volunteers
The third phase of the testing is also known as the Coronavirus Efficacy trial, where it could be determined whether Moderna’s COVID-19 vaccine candidate can ultimately help humans be immunized from the disease caused by the virus SARS-CoV-2.
The testing procedure will follow guidelines for clinical trials of vaccines set by the U.S. Food and Drugs Administration and will be conducted in “nearly 100” research locations in the country, according to Moderna. Phase 3 is expected to enroll 30,000 humans, but not all of them will be administered with a 100 µg dosage of the COVID-19 vaccine candidate.
NPR reports the volunteers will be divided into two groups, one of which will be given two separate shots of the mRNA-1273 with around 28 days interval. The other group will then be given injections of just saltwater. To maintain unbiased results, the volunteers and those who will administer the injections will not be informed to which group they belong.
Only the people handling the study will keep a record of who received which injections to later determine its effect on humans. People can learn more about the COVID-19 vaccine testing through ClinicalTrials.gov with identifier NCT04283461.
At the moment, there is no definite timeline when this phase of the trial will conclude because there are several factors to be considered, including the number of COVID-19 cases in a volunteer’s community. This means data gathering could take months, which corresponds to Dr. Anthony Fauci's earlier estimate that vaccine availability might not happen until 2021. In this sample size, COVID-19 infections should be limited to around 150 for the vaccine candidate to be determined as effective.
Potential COVID-19 vaccine immunized animals in an earlier trial
Moderna’s COVID-19 vaccine candidate has shown impressive results in earlier testing on non-human primates. The study published in The New England Journal of Medicine reports that eight animals that were challenged with the virus showed no viral replication two days after each received 100-μg doses of mRNA-1273 injections. The same research suggests the animals developed immunization from SARS-CoV-2 with “rapid protection in the upper and lower airways, and no pathologic changes in the lung.”
The COVID-19 vaccine candidate from Moderna utilizes the messenger RNA (mRNA) model that uses a genetic material of the SARS-CoV-2 that, when injected, instructs the system to produce a harmless protein found in the outer layer of the virus. This protein then tells the immune system to produce antibodies that will protect the body from the virus.
